Roche has terminated development of two Huntington's disease therapies partnered with Ionis Pharmaceuticals, dealing a setback to patients seeking treatments for the neurodegenerative disorder. The Swiss pharma giant informed patient groups that tominersen (RG6496) failed to delay disease progression in a clinical trial, while a separate drug candidate was scrapped due to a safety signal observed in animal testing.
The tominersen program had been one of the most advanced experimental therapies targeting Huntington's, a fatal genetic condition characterized by progressive motor and cognitive decline. The drug was designed to reduce production of the mutant huntingtin protein. Roche had previously paused a Phase 3 trial of tominersen in 2021 due to safety concerns but restarted a subcutaneous formulation study after adjusting the dosing regimen.
Roche did not disclose details about the second discontinued drug beyond the animal safety finding. The decision follows a broader pattern of high-risk failures in Huntington's drug development, where promising mechanisms have repeatedly fallen short in human trials. Several companies, including Wave Life Sciences and uniQure, continue pursuing alternative approaches.
For Ionis, the setback removes two pipeline assets that were among its most notable partnerships. The biotech's stock has faced pressure amid investor concerns about its dependence on collaborations with larger pharma firms. Roche's move underscores the difficulty of translating genetic insights into effective therapies for complex neurological diseases.
No timeline for potential market entry now exists for Roche's Huntington's pipeline. Patient groups expressed disappointment, while experts noted that the failures highlight the urgent need for better preclinical models to predict human trial outcomes. The drugmaker may redirect resources toward other neurology programs, including Alzheimer's and spinal muscular atrophy treatments.